Literature DB >> 20848168

Clinical ramifications of the MHC family Fc receptor FcRn.

Derry C Roopenian1, Victor Z Sun.   

Abstract

INTRODUCTION: Knowledge that antibodies of the IgG isotype have remarkably extended persistence in circulation and are able to pass through cell barriers has substantial implications. While it is well established that so-called neonatal Fc receptor, FcRn, acts throughout life to confer these unusual properties, its ramifications on clinical medicine and therapeutic uses are not broadly appreciated. SCOPE: Here we discuss basic principles and gaps in understanding of FcRn, including its management of IgG antibodies and along with albumin, its impact on use and design of antibody-based therapeutics, and its genetics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848168      PMCID: PMC3069705          DOI: 10.1007/s10875-010-9458-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  71 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

Review 2.  Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.

Authors:  Feng Jin; Joseph P Balthasar
Journal:  Hum Immunol       Date:  2005-04       Impact factor: 2.850

3.  Expression of the neonatal Fc receptor (FcRn) in the bovine mammary gland.

Authors:  Balázs Mayer; Márton Doleschall; Balázs Bender; János Bartyik; Zsuzsanna Bosze; László V Frenyó; Imre Kacskovics
Journal:  J Dairy Res       Date:  2005       Impact factor: 1.904

4.  THE METABOLISM OF NORMAL PLASMA PROTEINS AND GAMMA-MYELOMA PROTEIN IN MICE BEARING PLASMA-CELL TUMORS.

Authors:  J H Humphrey; J L Fahey
Journal:  J Clin Invest       Date:  1961-09       Impact factor: 14.808

Review 5.  Optimization of Fc-mediated effector functions of monoclonal antibodies.

Authors:  William R Strohl
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

Review 6.  Serum albumin.

Authors:  T Peters
Journal:  Adv Protein Chem       Date:  1985

7.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

8.  Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor.

Authors:  W P Burmeister; L N Gastinel; N E Simister; M L Blum; P J Bjorkman
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

9.  Association between polymorphisms in the FCGRT gene and lupus nephritis in Chinese patients.

Authors:  X-J Zhou; L Yu; L Zhu; P Hou; J-C Lv; F Yu; H Zhang
Journal:  Clin Exp Rheumatol       Date:  2009 Jul-Aug       Impact factor: 4.473

10.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

View more
  12 in total

Review 1.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

2.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

Review 3.  Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.

Authors:  Yulia Vugmeyster; John Harrold; Xin Xu
Journal:  AAPS J       Date:  2012-07-14       Impact factor: 4.009

4.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

5.  Extra-central nervous system target for assessment and treatment in refractory anti-N-methyl-d-aspartate receptor encephalitis.

Authors:  David W Nauen
Journal:  J Crit Care       Date:  2016-09-22       Impact factor: 3.425

6.  Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.

Authors:  Gabriele Proetzel; Derry C Roopenian
Journal:  Methods       Date:  2013-07-16       Impact factor: 3.608

7.  NFκB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn.

Authors:  Judit Cervenak; Márton Doleschall; Balázs Bender; Balázs Mayer; Zita Schneider; Zoltán Doleschall; Yaofeng Zhao; Zsuzsanna Bősze; Lennart Hammarström; Wolfgang Oster; Imre Kacskovics
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

8.  Engineering bispecificity into a single albumin-binding domain.

Authors:  Johan Nilvebrant; Tove Alm; Sophia Hober; John Löfblom
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

9.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

10.  Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.

Authors:  S Wickramaratne Senarath Yapa; D Roth; D Gordon; H Struemper
Journal:  Lupus       Date:  2016-07-11       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.